Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Celyad SA (NASDAQ: CYAD).

Full DD Report for CYAD

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYAD)

Celyad announces pricing of $47.3 million global offering
MONT-SAINT-GUIBERT, Belgium, May 17, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today announced the pricing of a global offering of 1,80...
Source: GlobeNewswire
Date: May, 17 2018 09:01
Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions
Analysis focus: BHVN Biohaven Pharmaceuticals (BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagoni...
Source: SeekingAlpha
Date: May, 17 2018 00:16
Celyad -3.3% after announcing 1.8M-unit offering
Clinical-stage biopharmaceutical firm Celyad (NASDAQ: CYAD ) is off 3.3% in U.S. trading after announcing a plan to sell 1.8M units in a global offering . More news on: Celyad, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 19:33
Celyad Announces First Quarter 2018 Business Update
Steady progress in THINK 1 , SHRINK 2 and LINK 3 trials MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T ce...
Source: GlobeNewswire
Date: May, 15 2018 16:46
Celyad announces launch of proposed global offering
MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today announces that it intends to offer and sell, subje...
Source: GlobeNewswire
Date: May, 15 2018 16:46
Key events next week - healthcare
Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:02
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
MONT-SAINT-GUIBERT, Belgium, May 09, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies,  today announced that the company will present recent advances in Celya...
Source: GlobeNewswire
Date: May, 09 2018 01:00
Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall
Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs...
Source: SeekingAlpha
Date: May, 07 2018 08:00
Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01
Celyad (NASDAQ: CYAD ) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well. More news on: Celyad, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 09:17
Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials
Celyad achieves important milestone in CYAD-01 treatment evaluation of metastatic colorectal cancer: No toxicity observed to date in first patient enrolled in the SHRINK 1 trial (concurrent administration of CYAD-01  with standard chemotherapy) No toxicity observed to dat...
Source: GlobeNewswire
Date: May, 03 2018 01:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1826.2826.0527.0025.55178,423
2018-05-1726.2826.0527.0025.55178,423
2017-03-1023.670822.2623.670821.30808
2017-03-0922.0022.5022.5022.007,875
2017-03-0822.8722.0022.8722.002,640

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1816,07122,06972.8216Short
2018-05-1710,14746,40221.8676Cover
2018-05-161,1551,38183.6350Short
2018-05-152,7554,67858.8927Short
2018-05-1412537633.2447Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYAD.


About Celyad SA (NASDAQ: CYAD)

Logo for Celyad SA (NASDAQ: CYAD)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CYAD)

      Free Writing Prospectus
      Filing Type: FWPFiling Source: edgar
      Filing Date: May, 16 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 03 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 06 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 01 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: November, 22 2017

       

       


      Daily Technical Chart for (NASDAQ: CYAD)

      Daily Technical Chart for (NASDAQ: CYAD)


      Stay tuned for daily updates and more on (NASDAQ: CYAD)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CYAD)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYAD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CYAD and does not buy, sell, or trade any shares of CYAD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/